Lumiere Therapeutics Co., Ltd.

Guangzhou Henovcom Bioscience Co. Ltd

Telefonaktiebolaget Lm Ericsson (publ)

Yang Hu

Muhammad Ali Kazmi

Xinghua Song

Jianfeng Wang

Jiansong Gan

Yin Liu

Lijun Zhang

Yu Qian

Jiancun Zhang

Danyang Liu

Yulin Yu

Wenqiong Tan

Shaoyun Lin

Bohong Chen

Jufu Zhang

Qingan Zou

Yanwei Chen

Ning Kang

Xiaojie Ma

Jiajun Yu

Wenchang Xu

Youyu Wu

Jinshuai Sun

Zhu Zhu

Yijun Huang

Disclosed herein are a Cas12i polypeptide and use thereof in a CRISPR-Cas system. Specifically disclosed herein are a Cas12i polypeptide, a Cas12i fusion polypeptide, a guide RNA, a complex formed by the Cas12i polypeptide or fusion polypeptide with the guide RNA, a nucleic acid, a vector, a vector system, a delivery system, a kit, a composition, and a method for modifying a nucleic acid using the components described above.

CRISPR-Cas systems and uses thereof

Disclosed are adenosine deaminases, base editors comprising the adenosine deaminases and complexes comprising the base editors. The adenosine deaminases and the base editors exhibited superior adenine editing effects and achieved A·T base pair to G·C base pair transformation at DNA level.

Engineered adenosine deaminases and base editors thereof

Provided are novel heteroaromatic compound as an Autotaxin inhibitor, a pharmaceutical composition comprising the compound, and a use thereof in a treatment of a disease with a pathological feature of Autotaxin overexpression in a mammal, wherein the compound is according to formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, or mixture thereof; wherein each of R, Ar, Ar, Ar, W, Y, Z, and Cy is defined in the present disclosure.

Aromatic heterocyclic compound, and pharmaceutical composition and use thereof

Growing community of inventors

Guangzhou, China

Yang Hu